Cladribine Use in Relapsing Multiple Sclerosis After 8-10 Years: Two Case Reports of Patients From the ORACLE-MS Study.

Cladribine is an immune reconstitution therapy for multiple sclerosis (MS) that selectively produces long-term reductions in highly pathological memory B cells, with temporary reductions in other B- and T-cell subsets, thereby restoring immune function close to baseline levels in the short term. Here, we describe two cases of relapsing MS (RMS) treated with a second course of cladribine. Both patients were initially diagnosed with clinically isolated syndrome and later enrolled in the ORACLE-MS and CLASSIC-MS studies.

Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study.

Background: There is a lack of head-to-head studies comparing the efficacy of fingolimod (FIN) and natalizumab (NTZ) as second-line therapy for relapsing-remitting multiple sclerosis (RRMS).

Methods: Multicenter, observational study, in which, information of 388 patients randomly selected and treated with FIN or NTZ in routine clinical practice was retrospectively collected with the main objective of comparing the annualized relapse rate (ARR) over the first year, after FIN or NTZ treatment initiation.

Results: Mean ARR during the first year of treatment was 0.

Idiopathic intracranial hypertension: descriptive analysis in our setting.

Introduction: Idiopathic intracranial hypertension is a disorder characterised by increased intracranial pressure without evidence of an expansive intracranial process or cerebrospinal fluid cytochemical alterations.

Patients And Method: We reviewed the medical records of patients with idiopathic intracranial hypertension admitted to our hospital between 1999 and 2009 and who met the modified Dandy criteria. We collected the following data: age, body mass index (BMI), outlet pressure of cerebrospinal fluid, cardiovascular history, imaging studies, treatment, and outcome.